These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 20368573)

  • 1. Rituximab and subcutaneous 2-chloro-2'-deoxyadenosine combination treatment for patients with Waldenstrom macroglobulinemia: clinical and biologic results of a phase II multicenter study.
    Laszlo D; Andreola G; Rigacci L; Fabbri A; Rabascio C; Mancuso P; Pruneri G; Radice D; Pinto A; Frigeri F; Calabrese L; Billio A; Bertolini F; Martinelli G
    J Clin Oncol; 2010 May; 28(13):2233-8. PubMed ID: 20368573
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rituximab and subcutaneous 2-chloro-2'-deoxyadenosine as therapy in untreated and relapsed Waldenström's macroglobulinemia.
    Laszlo D; Andreola G; Rigacci L; Fabbri A; Rabascio C; Pinto A; Negri M; Martinelli G
    Clin Lymphoma Myeloma Leuk; 2011 Feb; 11(1):130-2. PubMed ID: 21454213
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression of the human concentrative nucleotide transporter 1 (hCNT1) gene correlates with clinical response in patients affected by Waldenström's Macroglobulinemia (WM) and small lymphocytic lymphoma (SLL) undergoing a combination treatment with 2-chloro-2'-deoxyadenosine (2-CdA) and Rituximab.
    Rabascio C; Laszlo D; Andreola G; Saronni L; Radice D; Rigacci L; Fabbri A; Frigeri F; Calabrese L; Billio A; Bertolini F; Martinelli G
    Leuk Res; 2010 Apr; 34(4):454-7. PubMed ID: 19647871
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 2-Chlorodeoxyadenosine alone and in combination for previously untreated Waldenstrom's macroglobulinemia.
    Weber DM; Dimopoulos MA; Delasalle K; Rankin K; Gavino M; Alexanian R
    Semin Oncol; 2003 Apr; 30(2):243-7. PubMed ID: 12720145
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase 2 study of rituximab in combination with recombinant interleukin-2 for rituximab-refractory indolent non-Hodgkin's lymphoma.
    Khan KD; Emmanouilides C; Benson DM; Hurst D; Garcia P; Michelson G; Milan S; Ferketich AK; Piro L; Leonard JP; Porcu P; Eisenbeis CF; Banks AL; Chen L; Byrd JC; Caligiuri MA
    Clin Cancer Res; 2006 Dec; 12(23):7046-53. PubMed ID: 17145827
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fludarabine plus cyclophosphamide and rituximab in Waldenstrom macroglobulinemia: an effective but myelosuppressive regimen to be offered to patients with advanced disease.
    Tedeschi A; Benevolo G; Varettoni M; Battista ML; Zinzani PL; Visco C; Meneghini V; Pioltelli P; Sacchi S; Ricci F; Nichelatti M; Zaja F; Lazzarino M; Vitolo U; Morra E
    Cancer; 2012 Jan; 118(2):434-43. PubMed ID: 21732338
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase II trial of weekly bortezomib in combination with rituximab in untreated patients with Waldenström Macroglobulinemia.
    Ghobrial IM; Xie W; Padmanabhan S; Badros A; Rourke M; Leduc R; Chuma S; Kunsman J; Warren D; Poon T; Harris B; Sam A; Anderson KC; Richardson PG; Treon SP; Weller E; Matous J
    Am J Hematol; 2010 Sep; 85(9):670-4. PubMed ID: 20652865
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The addition of rituximab to fludarabine improves clinical outcome in untreated patients with ZAP-70-negative chronic lymphocytic leukemia.
    Del Poeta G; Del Principe MI; Consalvo MA; Maurillo L; Buccisano F; Venditti A; Mazzone C; Bruno A; Gianní L; Capelli G; Lo Coco F; Cantonetti M; Gattei V; Amadori S
    Cancer; 2005 Dec; 104(12):2743-52. PubMed ID: 16284990
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Primary treatment of Waldenström macroglobulinemia with dexamethasone, rituximab, and cyclophosphamide.
    Dimopoulos MA; Anagnostopoulos A; Kyrtsonis MC; Zervas K; Tsatalas C; Kokkinis G; Repoussis P; Symeonidis A; Delimpasi S; Katodritou E; Vervessou E; Michali E; Pouli A; Gika D; Vassou A; Terpos E; Anagnostopoulos N; Economopoulos T; Pangalis G
    J Clin Oncol; 2007 Aug; 25(22):3344-9. PubMed ID: 17577016
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fludarabine combination therapy is highly effective in first-line and salvage treatment of patients with Waldenström's macroglobulinemia.
    Tam CS; Wolf MM; Westerman D; Januszewicz EH; Prince HM; Seymour JF
    Clin Lymphoma Myeloma; 2005 Sep; 6(2):136-9. PubMed ID: 16231852
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Attainment of complete/very good partial response following rituximab-based therapy is an important determinant to progression-free survival, and is impacted by polymorphisms in FCGR3A in Waldenstrom macroglobulinaemia.
    Treon SP; Yang G; Hanzis C; Ioakimidis L; Verselis SJ; Fox EA; Xu L; Hunter ZR; Tseng H; Manning RJ; Patterson CJ; Sheehy P; Turnbull B
    Br J Haematol; 2011 Jul; 154(2):223-8. PubMed ID: 21564078
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of 72 newly diagnosed Waldenstrom macroglobulinemia cases with oral melphalan, cyclophosphamide, and prednisone: results and cost analysis.
    Annibali O; Petrucci MT; Martini V; Tirindelli MC; Levi A; Fossati C; Del Bianco P; Mandelli F; Foa R; Avvisati G
    Cancer; 2005 Feb; 103(3):582-7. PubMed ID: 15611977
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rituximab combined with cladribine or with cladribine and cyclophosphamide in heavily pretreated patients with indolent lymphoproliferative disorders and mantle cell lymphoma.
    Robak T; Smolewski P; Cebula B; Szmigielska-Kaplon A; Chojnowski K; Blonski JZ
    Cancer; 2006 Oct; 107(7):1542-50. PubMed ID: 16948126
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multicenter phase II trial of immunotherapy with the humanized anti-CD22 antibody, epratuzumab, in combination with rituximab, in refractory or recurrent non-Hodgkin's lymphoma.
    Strauss SJ; Morschhauser F; Rech J; Repp R; Solal-Celigny P; Zinzani PL; Engert A; Coiffier B; Hoelzer DF; Wegener WA; Teoh NK; Goldenberg DM; Lister TA
    J Clin Oncol; 2006 Aug; 24(24):3880-6. PubMed ID: 16864854
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase II trial of CHOP plus rituximab in patients with HIV-associated non-Hodgkin's lymphoma.
    Boué F; Gabarre J; Gisselbrecht C; Reynes J; Cheret A; Bonnet F; Billaud E; Raphael M; Lancar R; Costagliola D
    J Clin Oncol; 2006 Sep; 24(25):4123-8. PubMed ID: 16896005
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Weekly versus twice weekly bortezomib given in conjunction with rituximab, in patients with recurrent follicular lymphoma, mantle cell lymphoma and Waldenström macroglobulinaemia.
    Agathocleous A; Rohatiner A; Rule S; Hunter H; Kerr JP; Neeson SM; Matthews J; Strauss S; Montoto S; Johnson P; Radford J; Lister A
    Br J Haematol; 2010 Nov; 151(4):346-53. PubMed ID: 20880120
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lenalidomide and rituximab in Waldenstrom's macroglobulinemia.
    Treon SP; Soumerai JD; Branagan AR; Hunter ZR; Patterson CJ; Ioakimidis L; Chu L; Musto P; Baron AD; Nunnink JC; Kash JJ; Terjanian TO; Hyman PM; Nawfel EL; Sharon DJ; Munshi NC; Anderson KC
    Clin Cancer Res; 2009 Jan; 15(1):355-60. PubMed ID: 19118065
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pentostatin/cyclophosphamide with or without rituximab: an effective regimen for patients with Waldenstrom's macroglobulinemia/lymphoplasmacytic lymphoma.
    Hensel M; Villalobos M; Kornacker M; Krasniqi F; Ho AD
    Clin Lymphoma Myeloma; 2005 Sep; 6(2):131-5. PubMed ID: 16231851
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rituximab in combination with fludarabine and cyclophosphamide in the treatment of patients with recurrent follicular lymphoma.
    Sacchi S; Pozzi S; Marcheselli R; Federico M; Tucci A; Merli F; Orsucci L; Liberati M; Vallisa D; Brugiatelli M;
    Cancer; 2007 Jul; 110(1):121-8. PubMed ID: 17503433
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cladribine combined with rituximab (R-2-CdA) therapy is an effective salvage therapy in relapsed or refractory indolent B-cell non-Hodgkin lymphoma.
    Nagai H; Ogura M; Kusumoto S; Takahashi N; Yamaguchi M; Takayama N; Kinoshita T; Motoji T; Ohyashiki K; Kosugi H; Matsuda S; Ohnishi K; Omachi K; Hotta T
    Eur J Haematol; 2011 Feb; 86(2):117-23. PubMed ID: 21070370
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.